Although there was a trend towards a higher percentage of macrophages and T cells in the combination treatment group than the immunotherapy group, this difference did not reach statistical significance.
← all excerpts
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.
1
—
—